Shares of Georgia-headquartered GeoVax Labs, Inc. (GOVX) were rising more than 23 percent in pre-market trade after it announced an Assignment and License Agreement with PNP Therapeutics, Inc. that grants GeoVax exclusive rights to develop and commercialize Gedeptin, a novel patented product for the treatment of solid tumors.
from RTT - Before the Bell https://ift.tt/39SglRy
via IFTTT
No comments:
Post a Comment